Weekly Recap: Ulefnersen Phase 3 win in FUS-ALS and Sefaxersen UPCR hit

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) rallied after reporting positive Phase 3 FUSION topline results for ulefnersen and a 37—week interim win in Roche—linked IMAgINATION for sefaxersen in IgAN, with safety consistent, Roche collaboration confirmed and ARK Invest adding a ~$4.5M stake.Previous…